Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

BACKGROUND: This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Yonesaka, Kimio, Hayashi, Hidetoshi, Iwasa, Tsutomu, Haratani, Koji, Yamada, Hironori, Ohwada, Shoichi, Kamiyama, Emi, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344941/
https://www.ncbi.nlm.nih.gov/pubmed/28144730
http://dx.doi.org/10.1007/s00280-016-3231-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344941/
https://www.ncbi.nlm.nih.gov/pubmed/28144730
http://dx.doi.org/10.1007/s00280-016-3231-3

Ejemplares similares